LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager.
Corrales L, Hipp S, Martin K, Sabarth N, Tirapu I, Fuchs K, Thaler B, Walterskirchen C, Bauer K, Fabits M, Bergmann M, Binder C, Chetta PM, Vogt AB, Adam PJ.
Corrales L, et al. Among authors: thaler b.
Front Immunol. 2022 Sep 8;13:1008764. doi: 10.3389/fimmu.2022.1008764. eCollection 2022.
Front Immunol. 2022.
PMID: 36159851
Free PMC article.